MedTrace Logo

Evaluation of Naltrexone as a Treatment for Self-injurious Behavior

NCT02726035 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-11-06

No results posted yet for this study

Summary

The proposed study examines the effect of oral naltrexone on self-injurious behavior (SIB) in adolescents and adults of normal intelligence.

Conditions

  • Self-injurious Behavior
  • Self Mutilation

Interventions

DRUG

Naltrexone

oral naltrexone 50 mg daily

OTHER

Placebo

oral placebo (appearing identical to naltrexone) once daily

Sponsors & Collaborators

  • Kalamazoo Community Foundation

    collaborator OTHER

  • Western Michigan University School of Medicine

    lead OTHER

Principal Investigators

  • Michael R. Liepman, MD · Western Michigan University School of Medicine

  • Chris A. Karampahtsis, MD, MPH · Western Michigan University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-22
Primary Completion
2015-06-30
Completion
2017-01-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02726035 on ClinicalTrials.gov